Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this trial is to assess the efficacy and safety of using oral
verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the
patients' endogenous beta cell mass and insulin production. The objectives are therefore to
assess parameters of beta cell survival (including new biomarkers), insulin production and
glucose control and the feasibility of this approach and thereby provide the basis for
future, larger/expanded, longer-term verapamil studies and the off-label use of this approved
drug for Type 1 Diabetes (T1D).